drugset
drugset / Trial / NCT00367887

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

NCT00367887 ↗

Phase 2 Completed 246 enrolled Wyeth is now a wholly owned subsidiary of Pfizer ViroPharma · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders).

Timeline

Start
2006-10
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator NESBUVIR Small molecule 500 mg Oral
Comparator Peginterferon alfa-2b Protein / enzyme biologic — Subcutaneous
Comparator Ribavirin Small molecule — Oral

Indications

hepatitis C virus infection